Published in J Cell Mol Med on November 27, 2006
TGF-β in progression of liver disease. Cell Tissue Res (2011) 2.22
Hyperoxia-induced neonatal rat lung injury involves activation of TGF-{beta} and Wnt signaling and is protected by rosiglitazone. Am J Physiol Lung Cell Mol Physiol (2009) 1.50
50 years experience with Dupuytren's contracture in the Erlangen University Hospital--a retrospective analysis of 2919 operated hands from 1956 to 2006. BMC Musculoskelet Disord (2007) 1.27
Disruption of the Smad7 gene enhances CCI4-dependent liver damage and fibrogenesis in mice. J Cell Mol Med (2008) 0.91
Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation. Am J Pathol (2008) 0.88
Liver fibrosis secondary to bile duct injury: correlation of Smad7 with TGF-beta and extracellular matrix proteins. BMC Gastroenterol (2009) 0.84
Ingredients of Huangqi decoction slow biliary fibrosis progression by inhibiting the activation of the transforming growth factor-beta signaling pathway. BMC Complement Altern Med (2012) 0.83
A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine IFN signaling. J Immunol (2013) 0.77
Longitudinal in vivo bioimaging of hepatocyte transcription factor activity following cholestatic liver injury in mice. Sci Rep (2017) 0.75
Effect of Exogenous Fetuin-A on TGF-β/Smad Signaling in Hepatic Stellate Cells. Biomed Res Int (2016) 0.75
Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature (1997) 7.69
New insights into TGF-beta-Smad signalling. Trends Biochem Sci (2004) 6.13
Liver fibrosis -- from bench to bedside. J Hepatol (2003) 5.80
Roles of TGF-beta in hepatic fibrosis. Front Biosci (2002) 4.15
Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med (2006) 3.84
Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature (1999) 3.59
History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis (2001) 3.13
Smad3 as a mediator of the fibrotic response. Int J Exp Pathol (2004) 3.13
A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev (2000) 2.98
A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem (1981) 2.85
Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res (1987) 2.65
Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol (1984) 2.63
Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology (2004) 2.18
Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology (2003) 2.17
In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A (1999) 2.17
Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci U S A (1997) 2.15
Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci U S A (1999) 1.95
Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun (1998) 1.85
Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology (2000) 1.84
Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology (2002) 1.62
p38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology (2003) 1.55
Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology (2002) 1.52
Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology (2001) 1.32
Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. J Cell Physiol (2001) 1.17
Future perspectives in tissue engineering. J Cell Mol Med (2006) 1.15
Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology (2001) 1.06
Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J Biol Chem (1999) 1.03
Interaction between GC box binding factors and Smad proteins modulates cell lineage-specific alpha 2(I) collagen gene transcription. J Biol Chem (2001) 0.96
Expression of Smads during in vitro transdifferentiation of hepatic stellate cells to myofibroblasts. Biochem Biophys Res Commun (2001) 0.94
N-acetyl-L-cysteine abrogates fibrogenic properties of fibroblasts isolated from Dupuytren's disease by blunting TGF-beta signalling. J Cell Mol Med (2006) 0.88
Roles of TGF-beta in hepatic fibrosis. Front Biosci (2002) 4.15
Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A (1995) 3.25
The phosphorylation of liver ribosomal proteins in vivo. Evidence that only a single small subunit protein (S6) is phosphorylated. J Biol Chem (1974) 2.40
Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology (2003) 2.17
Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology (2008) 2.07
Practical implications of coexistent different technologies in clinical chemical laboratories. Solid phase chemistry and conventional analysis. Eur J Clin Chem Clin Biochem (1991) 1.96
The venous graft as an effector of early angiogenesis in a fibrin matrix. Microvasc Res (2007) 1.93
Tissue engineering of bone: the reconstructive surgeon's point of view. J Cell Mol Med (2006) 1.93
Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology (2000) 1.84
The synthesis of proteoglycans in fat-storing cells of rat liver. Hepatology (1987) 1.84
Primary mouse hepatocytes for systems biology approaches: a standardized in vitro system for modelling of signal transduction pathways. Syst Biol (Stevenage) (2006) 1.63
Skeletal muscle tissue engineering. J Cell Mol Med (2004) 1.63
Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis. J Clin Invest (1992) 1.62
Cryptosporidium parvum infection of Caco-2 cell monolayers induces an apical monolayer defect, selectively increases transmonolayer permeability, and causes epithelial cell death. Infect Immun (1994) 1.61
The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology (2008) 1.61
Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res (2010) 1.56
Fast track as a routine for open heart surgery. Eur J Cardiothorac Surg (2001) 1.56
Enhanced release of cytokines, interleukin-2 receptors, and neopterin after long-distance running. Clin Immunol Immunopathol (1992) 1.51
Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol (1997) 1.51
Experimental and modeling study of C5H10O2 ethyl and methyl esters. J Phys Chem A (2007) 1.51
Projected pain from noxious heat stimulation of an exposed peripheral nerve--a case report. Eur J Pain (2008) 1.46
Bilateral obstetric brachial plexus paralysis: a case report. Klin Padiatr (2009) 1.40
[The clinical value of laminin determination in advanced liver cirrhosis]. Dtsch Med Wochenschr (1996) 1.39
[Malignant bone tumors of the hand]. Handchir Mikrochir Plast Chir (2013) 1.39
Oral fluid collection by post for viral antibody testing. Int J Epidemiol (2001) 1.39
Outcome of infants born to hepatitis C infected women. Ir J Med Sci (2001) 1.38
Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology (1994) 1.38
Immunological measurement of transforming growth factor-beta 1 (TGF-beta1) in blood; assay development and comparison. Clin Chem (1997) 1.35
SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression. Blood (2009) 1.33
Autonomously vascularized cellular constructs in tissue engineering: opening a new perspective for biomedical science. J Cell Mol Med (2007) 1.31
TMEPAI, a transmembrane TGF-beta-inducible protein, sequesters Smad proteins from active participation in TGF-beta signaling. Mol Cell (2010) 1.30
Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts. Hepatology (2001) 1.29
Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. Hepatology (2006) 1.28
Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol (1997) 1.28
TGF-beta/Smad signaling in the injured liver. Z Gastroenterol (2006) 1.26
Tumor-dependent activation of rodent hepatic stellate cells during experimental melanoma metastasis. Hepatology (1997) 1.23
Transformation-dependent susceptibility of rat hepatic stellate cells to apoptosis induced by soluble Fas ligand. Hepatology (1998) 1.19
Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci U S A (1999) 1.19
Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology (2007) 1.19
Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24. Clin Nephrol (2009) 1.18
Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. Growth Factors (2005) 1.18
Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene (2009) 1.16
A new approach to tissue engineering of vascularized skeletal muscle. J Cell Mol Med (2006) 1.15
Tumor necrosis factor alpha (TNF alpha) and transforming growth factor beta 1 (TGF beta 1) stimulate fibronectin synthesis and the transdifferentiation of fat-storing cells in the rat liver into myofibroblasts. Virchows Arch B Cell Pathol Incl Mol Pathol (1993) 1.15
Functional and structural characterization of synthetic HIV-1 Vpr that transduces cells, localizes to the nucleus, and induces G2 cell cycle arrest. J Biol Chem (2000) 1.15
Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res (2005) 1.14
Influence of glucagon and cyclic adenosine 3':5'-monophosphate on the phosphorylation of rat liver ribosomal protein S6. J Biol Chem (1976) 1.11
Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells. Gut (2005) 1.11
Influence of hemodialysis on the mean blood flow velocity in the middle cerebral artery. Clin Nephrol (2005) 1.09
Phylogenetic analysis of Leishmania RNA virus and Leishmania suggests ancient virus-parasite association. Nucleic Acids Res (1995) 1.08
Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med (2007) 1.07
Increase in Mycobacterium avium complex isolations among patients admitted to a general hospital. Public Health Rep (1982) 1.07
Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology (2001) 1.06
The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. Int J Immunogenet (2007) 1.06
A novel serine/threonine-specific protein phosphotransferase activity of Nm23/nucleoside-diphosphate kinase. Eur J Biochem (1995) 1.05
Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat (2009) 1.05
Molecular and functional aspects of latent transforming growth factor-beta binding protein: just a masking protein? Cell Tissue Res (1999) 1.04
Evaluation of processed bovine cancellous bone matrix seeded with syngenic osteoblasts in a critical size calvarial defect rat model. J Cell Mol Med (2006) 1.04
Cochlear implant deep electrode insertion: extent of insertional trauma. Acta Otolaryngol (1997) 1.03
The stimulation of the phosphorylation of ribosomal protein S6 by cycloheximide and puromycin. Biochem Biophys Res Commun (1974) 1.03
Concern The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol (2007) 1.02
Neuropeptide Y: some viewpoints on a multifaceted peptide in the normal and diseased nervous system. Brain Res Brain Res Rev (1998) 1.02
Intrathecal morphine in a parturient with a single ventricle. Anesthesiology (1981) 1.02
TGF-beta enhances alcohol dependent hepatocyte damage via down-regulation of alcohol dehydrogenase I. J Hepatol (2010) 1.01
Prospective study of alcoholism treatment. Eight-year follow-up. Am J Med (1983) 1.01
Serum concentrations of laminin and aminoterminal propeptide of type III procollagen in relation to the portal venous pressure of fibrotic liver diseases. Clin Chim Acta (1986) 1.00
Localization of neuropeptide Y Y1 receptors in the rat nervous system with special reference to somatic receptors on small dorsal root ganglion neurons. Proc Natl Acad Sci U S A (1994) 1.00
Availability and usefulness of selected health and socioeconomic data for community planning. Am J Public Health Nations Health (1967) 1.00
Perimodiolar electrodes in cochlear implant surgery. Acta Otolaryngol (2001) 1.00
The Y-box binding protein YB-1 suppresses collagen alpha 1(I) gene transcription via an evolutionarily conserved regulatory element in the proximal promoter. J Biol Chem (2001) 0.99
Rapid genotyping of hemochromatosis gene mutations on the LightCycler with fluorescent hybridization probes. Clin Chem (1999) 0.99
Gallbladder metastasis from renal cell carcinoma mimicking acute cholecystitis. Eur J Med Res (2009) 0.99
Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver. J Am Soc Nephrol (2001) 0.99
The macrophage aggregation assay for cell-mediated immunity in man. Studies of patients with Hodgkin's disease and sarcoidosis. J Lab Clin Med (1973) 0.98
Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. J Hepatol (1996) 0.98
Isolation and characterization of the human mismatch repair gene hMSH2 promoter region. Hum Genet (1996) 0.98
Interaction of synthetic polynucleotides with small rat liver ribosomal subunits possessing low and highly phosphorylated protein S6. Biochim Biophys Acta (1980) 0.97
Fibroblast growth factor 16 and 18 are expressed in human cardiovascular tissues and induce on endothelial cells migration but not proliferation. Biochem Biophys Res Commun (2006) 0.97
Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem (2007) 0.97
Hepatic stellate cells display a functional vascular smooth muscle cell phenotype in a three-dimensional co-culture model with endothelial cells. Differentiation (2008) 0.97
Tissue-specific enhancer-promoter interactions regulate high level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells. J Biol Chem (1995) 0.97
Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV. Scand J Immunol (1989) 0.97
The effect of carpal tunnel release on median nerve flattening and nerve conduction. Electromyogr Clin Neurophysiol (2005) 0.97
Identification of human semaphorin E gene expression in rheumatoid synovial cells by mRNA differential display. Biochem Biophys Res Commun (1997) 0.96
Evaluation of blood vessel ingrowth in fibrin gel subject to type and concentration of growth factors. J Cell Mol Med (2008) 0.96
[Rehabilitation of patients with hearing loss by cochlear implants]. Radiologe (1997) 0.96
Are collagens the culprits in the development of incisional and inguinal hernia disease? Hernia (2006) 0.95
High levels of nm23-H1 and nm23-H2 messenger RNA in human squamous-cell lung carcinoma are associated with poor differentiation and advanced tumor stages. Int J Cancer (1993) 0.94
Single-cell suspensions of cultured human keratinocytes in fibrin-glue reconstitute the epidermis. Cell Transplant (1998) 0.94
LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1. Biochem J (2001) 0.94
Expression of Smads during in vitro transdifferentiation of hepatic stellate cells to myofibroblasts. Biochem Biophys Res Commun (2001) 0.94
Influence of polyglecaprone 25 (Monocryl) supplementation on the biocompatibility of a polypropylene mesh for hernia repair. Hernia (2005) 0.94
Effect of experimental diabetes and insulin on phosphorylation of rat liver ribosomal protein S6. Nature (1976) 0.93
Modulation of hepatic lipocyte proteoglycan synthesis and proliferation by Kupffer cell-derived transforming growth factors type beta 1 and type alpha. Biochem Biophys Res Commun (1990) 0.93